We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dr Alan Schafer to head Population Genetics as CEO
News

Dr Alan Schafer to head Population Genetics as CEO

Dr Alan Schafer to head Population Genetics as CEO
News

Dr Alan Schafer to head Population Genetics as CEO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dr Alan Schafer to head Population Genetics as CEO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dr Shafer is Adjunct Professor of Innovation at Imperial College London Business School and was previously the Wellcome Trust’s Director of Science Funding. Before that he served as Global Vice-President of Technology Development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company and subsequently acquired by Incyte. He will continue to serve on a number of research and venture capital advisory boards.

“We have validated our technology platforms and built important collaborations with world class clinical research groups and now look forward to the next phase in our development with Alan at the helm,” said Sam Eletr, a co-founder and Chairman of Population Genetics. “Our aim is to provide an efficient route for population-scale genetic analysis and biomarker discovery for application in medicine and agriculture”.

Commenting on his appointment as CEO Schafer added: “I am devoted to excellence in research and its application to improve health and human welfare and am pleased to be joining Population Genetics where the company’s talented staff, solid investor group, established capabilities and intellectual property portfolio will allow us to accelerate the application of genetics to improve human health by providing actionable information, not just sequencing data”.

Advertisement